Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Tci GeneROCO:6879 +0.41%65 EV-to-FCF is 1.17 as of Jul. 15, 2026, which is 93% below its 10-year median of 17.99. GuruFocus rates ROCO:6879 with a GF Score™ of 65/100 and a GF Value™ of NT$48.98 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 336 Biotechnology companies, Tci Gene ranks better than 75.3% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Tci Gene's Enterprise Value is NT$176.5 Mil.
Tci Gene's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was NT$150.9 Mil. Therefore, Tci Gene's EV-to-FCF for today is 1.17.
The historical rank and industry rank for Tci Gene's EV-to-FCF or its related term are showing as below:
ROCO:6879'
s EV-to-FCF Range Over the Past 10 Years
Min: 0.68 Med: 17.99 Max: 100.8
Current: 1.17
During the past 7 years, the highest EV-to-FCF of Tci Gene was 100.80. The lowest was 0.68. And the median was 17.99.
ROCO:6879's EV-to-FCF is ranked better than 75.3% of 336
companies
in the Biotechnology industry
Industry Median: 15.32
vs ROCO:6879: 1.17
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Tci Gene's share price for today is NT$36.65.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Tci Gene's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$1.520.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Tci Gene EV-to-FCF Related Terms
Tci Gene EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Tci Gene's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6879 vs VRTX, REGN, ALNY: EV-to-FCF Comparison
For the Biotechnology subindustry, Tci Gene's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tci Gene EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tci Gene's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Tci Gene's EV-to-FCF falls into.
Tci Gene's current Enterprise Value is NT$176.5 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Tci Gene's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was NT$150.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tci Gene (ROCO:6879) has a EV-to-FCF of 1.17 as of Jul. 15, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Tci Gene and its competitors. This is 93% below median its historical median of 17.99. Over the past decade, Tci Gene's EV-to-FCF has ranged from 0.68 to 100.80. According to the industry distribution chart, Tci Gene ranks #83 out of 336 companies in the Biotechnology industry, placing it in the top 24.7%.
Is Tci Gene's EV-to-FCF too high?
Tci Gene's current EV-to-FCF of 1.17 is 93% below median its 10-year median of 17.99. Over the past 10 years, this metric has ranged from a low of 0.68 to a high of 100.80. The Biotechnology industry median EV-to-FCF is 15.32. Tci Gene's value of 1.17 is 92.4% below this industry median. Based on the distribution chart, Tci Gene ranks #83 out of 336 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Tci Gene has a GF Score™ of 65/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Tci Gene's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Tci Gene ranks #83 out of 336 companies for EV-to-FCF. This places Tci Gene in the top 25% of its industry — outperforming the majority of peers. The industry median EV-to-FCF is 15.32. Tci Gene's value of 1.17 is 92.4% below this benchmark. Historically, Tci Gene's own EV-to-FCF has ranged from 0.68 to 100.80 over the past decade. While the company's 10-year median is 17.99 vs. the industry median of 15.32, Tci Gene has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 15.32, based on 336 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tci Gene's current EV-to-FCF of 1.17 is 92.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Tci Gene and its competitors. For the Biotechnology industry, the median EV-to-FCF is 15.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tci Gene's current EV-to-FCF is 1.17, which is 93% below median its own 10-year median of 17.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tci Gene stock overvalued right now?
Based on GuruFocus' analysis, Tci Gene (ROCO:6879) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$48.98, compared to a current price of NT$36.65 — trading 25.2% below its estimated fair value. The current EV-to-FCF is 1.17, which is 93% below median its 10-year median of 17.99 and 92.4% below the Biotechnology industry median of 15.32. Tci Gene's overall GF Score™ is 65/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Tci Gene (ROCO:6879), the current EV-to-FCF is 1.17 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tci Gene (ROCO:6879) Overvalued in 2026?
Based on GuruFocus' analysis, Tci Gene stock appears to be undervalued.
The current stock price of NT$36.65 is trading 25.2% below its estimated GF Value™ of NT$48.98.
GuruFocus considers Tci Gene to be Modestly Undervalued.
Key valuation signals for ROCO:6879:
EV-to-FCF: 1.17 (93% below median its 10-year median of 17.99)
GF Value™: NT$48.98 vs. price of NT$36.65 (25.2% below fair value)
Industry Position: 92.4% below the Biotechnology median (#83 of 336)
No single metric tells the full story. See the ROCO:6879 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tci Gene Inc provides precision preventive medicines in Taiwan. It is the first to introduce the concept of precision preventive medicine with Predict prediction, Prevent prevention, and Personal Treatment personalized health management measures.
65GF Score
Get the complete analysis for ROCO:6879
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6879 has been successfully added to your 
